Why did STERIS raise its revenue guidance but keep its EPS guidance unchanged?

The filing attributes the higher reported revenue outlook (8-9%, up from 6-7%) to a significant shift in foreign currency expectations, with about 200 basis points of favorability based on forward rates through March 31, 2026. The adjusted EPS range of $9.90 to $10.15 was unchanged because favorable currency effects are offset by increased tariffs (estimated at about $45 million pre-tax, up from $30 million) and higher employee healthcare benefit costs.

What is changing in STERIS's finance leadership?

Michael J. Tokich resigned as Senior Vice President and CFO, and Karen Burton will succeed him effective August 18, 2025. Burton, age 58, has been Vice President and Chief Accounting Officer since January 2017. Tokich will remain as a senior financial advisor until March 31, 2026, at a reduced base salary of $427,450.14, with his outstanding equity awards continuing to vest.

What compensation changes apply to the new CFO?

Burton's base salary will increase to an annual rate of $600,000, and her MICP target bonus will rise to 75% of base salary. She is also slated to receive an equity award of restricted stock and stock options with an aggregate value of approximately $1,134,000, effective October 1, 2025. Her severance benefits remain under the STERIS plc Senior Executive Severance Plan.

What drove segment performance in the quarter?

Healthcare revenue rose 8% to $974.7 million, with operating income of $235.5 million, reflecting volume, price, productivity and restructuring benefits partly offset by tariffs and inflation. AST revenue rose 13% to $281.2 million, with segment operating income of $136.7 million, reflecting improved price and volume that more than offset higher energy costs and labor inflation. Life Sciences revenue rose 5% to $135.2 million, with operating income of $58.7 million.

How did shareholders vote at the July 31, 2025 annual meeting?

Shareholders elected all nine director nominees, each for a one-year term. They also ratified Ernst & Young LLP as the independent registered public accounting firm for the year ending March 31, 2026, approved Ernst & Young Chartered Accountants as Irish statutory auditor, and approved the non-binding advisory say-on-pay proposal. Dr. Jaqueline Kosecoff and Dr. Richard Steeves retired from the Board, and Louis Shapiro was elected to it.

STE 8-K: Earnings & Results, Leadership Changes & More

01—Abstract

Summary

Summary of the 8-K filed August 6, 2025. Cited figures are marked; the original filing is the authoritative source.

STERIS plc (NYSE: STE) reported fiscal 2026 first-quarter results for the quarter ended June 30, 2025, with total revenue from continuing operations up 9% to $1.4 billion^a (1,391.1 million vs. 1,279.5 million).

Constant currency organic revenue grew 8%. Net income from continuing operations attributable to shareholders was $177.4 million^b, or $1.79 per diluted share, versus $139.8 million, or $1.41, a year earlier. Adjusted net income was $231.2 million, or $2.34 per diluted share, compared with $2.03 in the prior-year quarter.

Operating cash flow was $420.0 million^c and free cash flow was $326.5 million, versus $195.7 million a year earlier. Segment results showed growth across Healthcare, Applied Sterilization Technologies (AST) and Life Sciences. The company raised its fiscal 2026 revenue outlook to 8-9% growth, reported as revenue from continuing operations, from a prior 6-7%, citing roughly 200 basis points of favorable foreign currency.

Constant currency organic growth expectations were unchanged at 6-7%, and adjusted EPS guidance was held at $9.90 to $10.15^d, with favorable currency offset by higher tariffs (now estimated at about $45 million pre-tax impact versus $30 million previously) and higher employee healthcare costs. Free cash flow guidance was raised to approximately $820 million from $770 million on working capital improvements. The filing also discloses a CFO transition: Michael J.

Tokich resigned as Senior Vice President and CFO, and Karen Burton, the current Vice President and Chief Accounting Officer, will succeed him effective August 18, 2025. Tokich will serve as a senior financial advisor through March 31, 2026. At the July 31, 2025 annual meeting, shareholders elected all nine director nominees and approved the auditor ratification and non-binding say-on-pay proposal, among other matters.

02—Key points

Key Highlights

Q1 fiscal 2026 revenue from continuing operations rose 9% to $1.4 billion; constant currency organic growth was 8%.
GAAP diluted EPS from continuing operations was $1.79 versus $1.41; adjusted diluted EPS was $2.34 versus $2.03.
Operating cash flow was $420.0 million and free cash flow was $326.5 million, up from $303.7 million and $195.7 million, respectively.
Fiscal 2026 reported revenue growth outlook raised to 8-9% from 6-7%, driven by roughly 200 basis points of favorable foreign currency; constant currency organic growth outlook unchanged at 6-7%.
Adjusted EPS outlook held at $9.90 to $10.15; estimated tariff impact increased to about $45 million pre-tax from $30 million.
Free cash flow outlook raised to approximately $820 million from $770 million, citing working capital improvements.
CFO Michael J. Tokich is stepping down; Karen Burton, Vice President and Chief Accounting Officer, becomes Senior Vice President and CFO on August 18, 2025, with a base salary of $600,000.

03—Questions

Frequently Asked Questions

Why did STERIS raise its revenue guidance but keep its EPS guidance unchanged?
The filing attributes the higher reported revenue outlook (8-9%, up from 6-7%) to a significant shift in foreign currency expectations, with about 200 basis points of favorability based on forward rates through March 31, 2026. The adjusted EPS range of $9.90 to $10.15 was unchanged because favorable currency effects are offset by increased tariffs (estimated at about $45 million pre-tax, up from $30 million) and higher employee healthcare benefit costs.
What is changing in STERIS's finance leadership?
Michael J. Tokich resigned as Senior Vice President and CFO, and Karen Burton will succeed him effective August 18, 2025. Burton, age 58, has been Vice President and Chief Accounting Officer since January 2017. Tokich will remain as a senior financial advisor until March 31, 2026, at a reduced base salary of $427,450.14, with his outstanding equity awards continuing to vest.
What compensation changes apply to the new CFO?
Burton's base salary will increase to an annual rate of $600,000, and her MICP target bonus will rise to 75% of base salary. She is also slated to receive an equity award of restricted stock and stock options with an aggregate value of approximately $1,134,000, effective October 1, 2025. Her severance benefits remain under the STERIS plc Senior Executive Severance Plan.
What drove segment performance in the quarter?
Healthcare revenue rose 8% to $974.7 million, with operating income of $235.5 million, reflecting volume, price, productivity and restructuring benefits partly offset by tariffs and inflation. AST revenue rose 13% to $281.2 million, with segment operating income of $136.7 million, reflecting improved price and volume that more than offset higher energy costs and labor inflation. Life Sciences revenue rose 5% to $135.2 million, with operating income of $58.7 million.
How did shareholders vote at the July 31, 2025 annual meeting?
Shareholders elected all nine director nominees, each for a one-year term. They also ratified Ernst & Young LLP as the independent registered public accounting firm for the year ending March 31, 2026, approved Ernst & Young Chartered Accountants as Irish statutory auditor, and approved the non-binding advisory say-on-pay proposal. Dr. Jaqueline Kosecoff and Dr. Richard Steeves retired from the Board, and Louis Shapiro was elected to it.

04—Continue

← View all 8-K filings